Preventing peptide-induced anaphylaxis: addition of C-terminal amino acids to produce a neutral isoelectric point.
暂无分享,去创建一个
F. Finkelman | G. Eisenbarth | H. Moriyama | E. Liu | D. Devendra | N. Abiru | J. Paronen
[1] H. Mcdevitt,et al. Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus , 2003, BMC Immunology.
[2] A. Kay,et al. Peptide-based vaccines in the treatment of specific allergy. , 2002, Current drug targets. Inflammation and allergy.
[3] F. Finkelman,et al. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. , 2002, The Journal of clinical investigation.
[4] O. Lehoczky,et al. [Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction]. , 2002, Orvosi hetilap.
[5] F. Finkelman,et al. Pathways of anaphylaxis in the mouse. , 2002, The Journal of allergy and clinical immunology.
[6] David Fear,et al. The biology of IGE and the basis of allergic disease. , 2001, Annual review of immunology.
[7] N. Sarvetnick,et al. Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection. , 2001, Clinical immunology.
[8] R. Pedotti,et al. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide , 2001, Nature Immunology.
[9] A. Evans,et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial , 2000, Nature Medicine.
[10] J. Frank,et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.
[11] L Heinemann,et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. , 2000, Diabetes care.
[12] M. Rewers,et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[13] D. Umetsu,et al. The safety and efficacy of ALLERVAX CAT in cat allergic patients. , 1999, Clinical immunology.
[14] M. Manning,et al. Preparation and in vitro characterization of gentamycin-impregnated biodegradable beads suitable for treatment of osteomyelitis. , 1998, Journal of pharmaceutical sciences.
[15] D. MacGlashan,et al. IgE-mediated desensitization in human basophils and mast cells. , 1998, Frontiers in bioscience : a journal and virtual library.
[16] M. Manning,et al. Hydrophobic Ion Pairing: Altering the Solubility Properties of Biomolecules , 1998, Pharmaceutical Research.
[17] M. Manning,et al. Drug delivery matrix containing native protein precipitates suspended in a poloxamer gel. , 1997, Journal of pharmaceutical sciences.
[18] S. Galli,et al. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. , 1997, The Journal of clinical investigation.
[19] K. Shokat,et al. Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[20] D. Wegmann,et al. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[21] H. Weiner,et al. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. , 1994, Proceedings of the National Academy of Sciences of the United States of America.